Showing 1 - 3 results of 3 for search 'Y. Ofran', query time: 0.02s Refine Results
  1. 1
    P578: GILTERITINIB FOR RELAPSED/REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA A REAL-WORLD, MULTI-CENTER, MATCHED ANALYSIS

    P578: GILTERITINIB FOR RELAPSED/REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA A REAL-WORLD, MULTI-CENTER, MATCHED ANALYSIS by S. Shimony, J. Canaani, E. Kugler, B. Nachmias, R. Ram, A. Frisch, C. Ganzel, V. Vainstein, Y. Moshe, S. Aumann, M. Yeshurun, Y. Ofran, P. Raanani, O. Wolach

    Published 2022-06-01
    Get full text
    Article
  2. 2
    P585: VENETOCLAX IN COMBINATION WITH INTENSIVE TREATMENT PROTOCOLS FOR PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA – A MULTICENTER REAL-WORLD ANALYSIS

    P585: VENETOCLAX IN COMBINATION WITH INTENSIVE TREATMENT PROTOCOLS FOR PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA – A MULTICENTER REAL-WORLD ANALYSIS by O. Wolach, A. Frisch, L. Shargian, M. Yeshurun, A. Apel, V. Vainstein, Y. Moshe, S. Shimony, O. Amit, Y. Bar On, Y. Ofran, P. Raanani, B. Nachmias, R. Ram

    Published 2022-06-01
    Get full text
    Article
  3. 3
    PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)

    PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT... by A. DeZern, G. Marconi, D. Deeren, M. Diez Campelo, M. Lübbert, P. Krishnamurthy, Z. Nagy, G. Basak, A. Jonášová, E. Morozova, K. Geissler, Y. Ofran, H. Kelley, A. Volkert, K. Baker, Q. Kang-Fortner, G. Hodgson, C. Madigan, D. A. Roth, M. Kelly, P. Fenaux

    Published 2022-06-01
    Get full text
    Article

Search Tools: